Loading
Latest filing published 08 Sept 2023 for Homology Medicines, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Albert Seymour (senior executive) discloses dealings in Q32 Bio Inc. to SEC (Form 4). The record holds 4 filings, for trades running from 1 January 2022 to 6 September 2023.
Every open-market trade on record is a sale: 1 sale worth €4,723. Besides market trades, the filings include 3 option exercises. 2023 to date brings no purchases and 1 sale.
Most recently, on 8 September 2023, the filings show an option exercise in Q32 Bio Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations